The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 10, 2011, Pages 2057-2070

  Kelly, Kevin R ^a   Ecsedy, Jeffrey ^b   Medina, Ernest ^a   Mahalingam, Devalingam ^a   Padmanabhan, Swaminathan ^a   Nawrocki, Steffan T ^a   Giles, Francis J ^a   Carew, Jennifer S ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Apoptosis; Aurora kinase A; BCR ABL; Cancer; CML; Kinase inhibitors

Indexed keywords

4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ALISERTIB; ANTINEOPLASTIC AGENT; AURORA KINASE; AZEPINE DERIVATIVE; BCR ABL PROTEIN; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; BIRC6 PROTEIN, HUMAN; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL STRAIN K 562; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MUTATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZEPINES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79957528550     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01218.x     Document Type: Article

References (41)

1. Druker BJ, Guilhot F, O'Brien SG, et al Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-17.
2. de Lavallade H, Apperley JF, Khorashad JS, et al Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26: 3358-63.
3. Talpaz M, Silver RT, Druker BJ, et al Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 1928-37.
4. Volpe G, Panuzzo C, Ulisciani S, et al Imatinib resistance in CML. Cancer letters. 2009; 274: 1-9.
5. Weisberg E, Manley PW, Breitenstein W, et al Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer cell. 2005; 7: 129-41.
6. Shah NP, Tran C, Lee FY, et al Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399-401.
7. Puttini M, Coluccia AM, Boschelli F, et al In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer research. 2006; 66: 11314-22.
8. Warner SL, Stephens BJ, Von Hoff DD. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep. 2008; 10: 122-9.
9. Ikezoe T, Yang J, Nishioka C, et al A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Molecular Cancer Ther. 2007; 6: 1851-7.
10. Harrington EA, Bebbington D, Moore J, et al VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10: 262-7.
11. Giles FJ, Cortes J, Jones D, et al MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007; 109: 500-2.
12. Gontarewicz A, Balabanov S, Keller G, et al Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008; 111: 4355-64.
13. Cortes-Franco J, Dombret H, Schafhausen P, et al Danusertib hydrochloride (PHA-739358), a multi-kinase Aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. ASH Annual Meeting. Washington Blood J.; 2009. p. 864.
14. Dai Y, Chen S, Venditti CA, et al Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood. 2008; 112: 793-804.
15. Fiskus W, Wang Y, Joshi R, et al Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res. 2008; 14: 6106-15.
16. Donato NJ, Fang D, Sun H, et al Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol. 2010; 79: 688-97.
17. Fu J, Bian M, Jiang Q, et al Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007; 5: 1-10.
18. Marumoto T, Honda S, Hara T, et al Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem. 2003; 278: 51786-95.
19. Hoar K, Chakravarty A, Rabino C, et al MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007; 27: 4513-25.
20. Sells T, Ecsedy J, Stroud S, et al MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. Philadelphia American Association for Cancer Research; 2008; 237.
21. Carew JS, Nawrocki ST, Krupnik YV, et al Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 2006; 107: 222-31.
22. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95: 3498-505.
23. Swords RT, Kelly KR, Smith PG, et al Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood. 2010; 115: 3796-800.
24. Nawrocki ST, Carew JS, Maclean KH, et al Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008; 112: 2917-26.
25. Carew JS, Nawrocki ST, Reddy VK, et al The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res. 2008; 68: 4783-90.
26. Carew JS, Nawrocki ST, Kahue CN, et al Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007; 110: 313-22.
27. Di Bacco A, Keeshan K, McKenna SL, et al Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist. 2000; 5: 405-15.
28. Wendel HG, de Stanchina E, Cepero E, et al Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA. 2006; 103: 7444-9.
29. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004; 432: 307-15.
30. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110: 2242-9.
31. Shah NP, Skaggs BJ, Branford S, et al Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007; 117: 2562-9.
32. Chen Z, Naito M, Hori S, et al A human IAP-family gene, Apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999; 264: 847-54.
33. Hao Y, Sekine K, Kawabata A, et al Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol. 2004; 6: 849-60.
34. Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem. 2005; 280: 174-82.
35. Sung KW, Choi J, Hwang YK, et al Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2007; 13: 5109-14.
36. Pohl C, Jentsch S. Final stages of cytokinesis and midbody ring formation are controlled by BRUCE. Cell. 2008; 132: 832-45.
37. Young MA, Shah NP, Chao LH, et al Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006; 66: 1007-14.
38. Carter TA, Wodicka LM, Shah NP, et al Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA. 2005; 102: 11011-6.
39. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer. 2005; 5: 42-50.
40. Martin SJ. An Apollon vista of death and destruction. Nat Cell Biol. 2004; 6: 804-6.
41. Quintás-Cardama A, Gibbons DL, Kantarjian HM, et al Mutational analysis of chronic phase chronic myeloid leukemia (CMLCP) clones reveals heightened BCR-ABL1 genetic instability in patients failing sequential imatinib and dasatinib therapy. ASH Annual Meeting Abstracts. Washington Blood J.; 112: 2114.